Loading search results
Sponsor study identifier
interventional
300
1 country
1
Study Start
August 16, 2021
Actual (reported)Primary Completion
December 31, 2022
Actual (reported)Study Completion
May 31, 2023
Actual (reported)In recent years, returning genetic results to research participants has become a topic of debate, with a growing consensus that researchers should offer to return incidental findings and research results to participants. Currently, the research and debates surrounding return of results (ROR) have primarily taken place in high-income countries. Less attention has been paid to ROR in lower-resource countries. However, research participants in these settings may have additional threats, barriers, and/or competing interests that reduce the benefit or relevance of receiving genetic results. Arsenic is a toxic metal. Exposure to arsenic increases a person's risk for cancer, especially in the lung, kidney, bladder and skin. Many people in Bangladesh are exposed to elevated environmental levels of arsenic through naturally contaminated drinking water. People who metabolize arsenic (remove it from their body) slower compared to people who metabolize arsenic more efficiently are at higher risk for arsenic toxicities (e.g. cancer). The investigators have designed a study in which they plan to enroll individuals who have had consistently high urine As levels (≥200 µg/g creatinine) based on 15-20 years of follow-up data. The treatment and control groups will be selected based on genotype (i.e. inefficient and efficient As metabolizers, respectively), allowing for the selection of the groups to be quasi-random (based on inherited genotypes). A standard informational intervention will be provided to both the treatment and controls groups, reminding them of the effects of As exposure and strategies to reduce their exposure. The research question is whether the treatment group will, have a larger decrease in urine arsenic levels compared to the control group, indicating that the ROR intervention caused a change in water-seeking behavior leading to lower arsenic exposure.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
May 31, 2023
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 16, 2021
Actual (reported)September 15, 2021
Actual (reported)October 8, 2021
Actual (reported)December 31, 2022
Actual (reported)May 31, 2023
Actual (reported)change in arsenic concentration in urine
Urine samples will be obtained by URB study staff at baseline (Time1 or initial contact) and Time2 (Six months after the onset of the intervention). Urine arsenic will be measured using Inductively Coupled Plasma Mass spectrometry (ICPMS) at the CACHET (The Chicago Center for Health and Environment) biomarkers core facility at UIC (University of Illinois at Chicago). The difference between arms in the change in arsenic from time 1 to time 2 will be assessing using regression-based statistical methods.
six months
Psychological stress
six months
Participants will be selected based on being inefficient arsenic metabolizers. A standard informational intervention will be provided, reminding them of the effects of arsenic exposure and strategies to reduce their exposure. This intervention group will additionally be provided information on their arsenic metabolism efficiency (i.e., their genetic results indicating they are inefficient metabolizers and at increased risk for arsenic toxicities).
Participants will be selected based on being efficient arsenic metabolizers. A standard informational intervention will be provided, reminding them of the effects of arsenic exposure and strategies to reduce their exposure. This intervention group will additionally be provided information on their arsenic metabolism efficiency (i.e., their genetic results indicating they are efficient metabolizers and at decreased risk for arsenic toxicities).
The intervention groups will receive information regarding their genetic results that informs them of their arsenic metabolism efficiency. They will receive this information through a factsheet appropriate for a lay audience. The factsheet will contain information regarding arsenic metabolism and its role in removing arsenic from the body. The factsheet will describe how there is variability among individuals with respect to the efficiency with which arsenic is removed from the body, due to inherited differences in genes that affect arsenic metabolism. The factsheet describe how slower metabolizers remove arsenic slower from the body, which leads to increased in toxicity risk. The factsheet will inform participants in the intervention groups that they have been identified as a slow/fast metabolizer of arsenic based on their genes. This information will be given to participants by the URB staff, with a study physician available to address questions and concerns from the participant.
UChicago Research Bangladesh
Dhaka, Dhaka-1230, Bangladesh
300 participants (actual enrollment reported by the registry).
First Submitted
September 15, 2021
First Posted
October 8, 2021
Study Start
August 16, 2021
Actual (reported)The control group will consist of a random sample of HEALS participants. A standard informational intervention will be provided, reminding them of the effects of arsenic exposure and strategies to reduce their exposure. No information on arsenic metabolism efficiency will be provided during the study period (option to receive after the study)
In this study, intervention and control groups will receive a standard informational intervention which will remind them of the effects of arsenic exposure and potential strategies that can be implemented to reduce their exposure.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
December 31, 2022
Actual (reported)Study Completion
May 31, 2023
Actual (reported)Last Updated
May 8, 2024
Record last verified: 2024-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: